National Cancer Institute (NCI) will Participate in PAR-13-109 "Mechanistic Insights from Birth Cohorts (R01)"

Notice Number: NOT-CA-13-002

Release Date: February 14, 2013

PAR-13-109

National Cancer Institute (NCI)

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) has been added to the participating components for PAR-13-109, entitled "Mechanistic Insights from Birth Cohorts (R01)."

Accordingly, in Part 1. Overview Information, the Components of Participating Organizations section has been revised as shown below to include the NCI:

Components of Participating Organizations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Heart, Lung, and Blood Institute (NHLBI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)

In Part 1. Overview Information, the Catalog of Federal Domestic Assistance Numbers section has been revised as shown below to include the appropriate number of the NCI, which is 93.399:

Catalog of Federal Domestic Assistance Numbers

93.847, 93.865, 93.838, 93.839, 93.399

In Part 2. Full Text of Announcement, Section I. Funding Opportunity Description, the following three sentences are each revised by the addition of "or cancer" to state:

"Little is known about the mechanisms by which such prenatal exposures lead to diabetes or obesity, renal, pulmonary, or cardiovascular or hematologic disease, neurodevelopmental disorders, reproductive health (i.e. fertility), or cancer." (This sentence is the second sentence under Background.)

"Studies proposed in response to this announcement must take advantage of existing (or accruing) birth cohorts, with well-characterized pregnancies, such that targeted mechanistic questions regarding the developmental origins of diabetes or obesity, renal, pulmonary, or cardiovascular or hematologic disease, neurodevelopmental disorders, reproductive health (i.e. fertility), or cancer can be addressed." (This sentence is the first sentence of the first paragraph under Scope and Areas of Research.)

"Applications in response to this FOA should target diabetes or obesity, renal, pulmonary, or cardiovascular or hematologic disease, neurodevelopmental disorders, reproductive health (i.e. fertility), or cancer." (This sentence is the first sentence of the fourth paragraph under Scope and Areas of Research Interest.)

In Part 2. Section VII. Agency Contacts, under Scientific/Research Contact(s), the name and contact information for the NCI's program representative are added as follows:

Somdat Mahabir, Ph.D., M.P.H.
Program Director
Modifiable Risk Factors Branch
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Boulevard, EPN Room 5138, MSC 7324
Bethesda, MD 20892-7324
Telephone: 301-496-0270
Email: mahabir@mail.nih.gov

In Part 2. Section VII. Agency Contacts, under Financial/Grants Management Contact(s), the name and contact information for the NCI's grants management representative are added as follows:

Funmi Elesinmogun

Grants Management Specialist
Office of Grants Administration 
National Cancer Institute
6120 Executive Boulevard, EPS Suite 243
Rockville, Maryland  20892-7150 (for regular mail)
Rockville, Maryland  20852 (for express delivery)
Telephone: 301-496-7245
Email: elesinmf@mail.nih.gov

All other aspects of the FOA remain the same.

Please direct all inquiries regarding this Notice to:

Somdat Mahabir, Ph.D., M.P.H.
National Cancer Institute
Telephone: 301-496-0270
Email: mahabir@mail.nih.gov